Immunex Corporation

Amgen Inc.

Other

The United States of America as Represented by the Department of Health

Qilu Puget Sound Biotherapeutics Corporation

William Christian Fanslow, Iii

Melanie K Spriggs

Richard Jeffrey Armitage

Zhengbin Yao

Subhashini Srinivasan

Marylou G Gibson

Peter Robert Baum

Arvia Eleanor Morris

Jeffrey T McGrew

Jean Marie Gudas

Carl Kozlosky

Chadwick Terence King

Raymond G Goodwin

John M Delaney

Richard B Gayle, Iii

Mark R Alderson

Wayne Richard Gombotz

Zhi Liu

Wei Yan

William J Murphy

Dan L Longo

Michael B Widmer

Zhonghua Hu

JoDee Zappone

Siow Fong Wee

The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.

Anti-mesothelin binding proteins

Anti-CTLA4 antibodies, anti-PD1 antibodies, mixtures thereof, polynucleotides encoding such antibodies or mixtures, optionally carried on vectors, and methods of treatment utilizing such antibodies, mixtures, polynucleotides, or vectors are described herein. The anti-CTLA4 and anti-PD1 antibodies have particular sequences and properties. The methods of treatment include uses in treatment of cancer, infections, and immunodeficiency disorders.

Anti-PD1 and anti-CTLA4 antibodies

The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.

CD27L antigen binding proteins

The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.

Antibodies that bind LDCAM

Polynucleotides encoding molecules designated LDCAM

Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Methods of treating asthma by administering interleukin-17 receptor

Molecules designated LDCAM

There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.

Mouse CD40 ligand-specific antibodies and hybridomas

Methods of treating allergy by administering interleukin-17 receptor

Methods of treating autoimmune disease by administering interleukin-17 receptor

DNA encoding CD40 ligand, a cytokine that binds CD40

There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of simulating hybridoma cells to increase monoclonal antibody production by administering a CD40 ligand polypeptide that stimulates B cell proliferation.

Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells

Growing community of inventors

Normandy Park, WA, United States of America

William Christian Fanslow, Iii